LOKELMATM Sodium Zirconium Cyclosilicate

SWIFT* K+ REDUCTION AFTER ONE HOUR.1,2
SUSTAINED K+ CONTROL FOR UP TO ONE YEAR
WHEN USED AS A MAINTENANCE THERAPY.†1
NOW IN YOUR HANDS.
New, highly-selective LOKELMA (sodium zirconium cyclosilicate)
is indicated for the treatment of hyperkalaemia in adult patients1

*In an emergency situation, standard of care should be used in line with local or national guidelines
Clinical trials with LOKELMA have not included exposure longer than one year

Clinical Studies

005 Study Overview

ZS005 was an open-label, multicentre, multidose maintenance-dose titration trial to investigate the long-term safety
and efficacy of LOKELMA in patients with hyperkalaemia. Hyperkalaemic patients (n=751) with K+ levels of ≥5.1 mmol/L received LOKELMA for 24–72 h to achieve normokalaemia. Once in the normokalaemia range, patients were enrolled in the extended dosing phase and received 5 g of LOKELMA once daily. K+ levels were assessed throughout the first month and every 4 weeks thereafter through month 12. During the extension phase the dosages were adjusted based on K+,
with patients taking either 5 g, 10 g or 15 g once daily or 5 g every other day.*4

Primary endpoint4

  • Restoration and maintenance of normokalaemia (3.5–5.0 mmol/L)

Secondary endpoints4

  • Proportion of subjects with normokalaemia (3.5–5.5 mmol/L) months 3–12
  • Mean serum K+ values months 3–12, 6–9 and 9–12
  • Change (absolute and percent) from acute phase K+ values
  • Change (absolute and percent) from acute phase bicarbonate values
  • Proportion of subjects with normal bicarbonate

LOKELMA 005 study overview4

ZS005 was an open-label, multicentre, multidose maintenance-dose titration trial
ZS005 was an open-label, multicentre, multidose maintenance-dose titration trial

*LOKELMA 15 g is not approved for use in the UK.